FCCC LOGO Faculty Publications
Cohen SJ , Engstrom PF , Lewis NL , Langer CJ , McLaughlin S , Beard M , Weiner LM , Meropol NJ
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors
American Journal of Clinical Oncology-Cancer Clinical Trials. 2008 Feb;31(1) :1-5
PMID: ISI:000253102700001   
Back to previous list
Abstract
Purpose: The combination of capecitabine and oxaliplatin has clinical benefit in a variety of gastrointestinal malignancies. The proteasome inhibitor bortezomib enhances the cytotoxic activity of fluoropyrimidines and platinum agents in vivo, and targeting of NF-kappa B may overcome chemotherapy resistance. Thus, we performed this phase I study to document the safety and obtain preliminary efficacy data for the combination of capecitabine, oxaliplatin, and bortezomib. Patients and Methods: Patients with advanced solid tumors were treated with oxaliplatin 130 mg/m(2) intravenously on day 1, capecitabine 750-900 mg/m(2) twice daily orally for 14 days, and bortezomib 1.0, 1.3, or 1.6 mg/m(2) intravenously on days 1 and 8 of 21 day cycles. CT scans were repeated every 2 cycles. Results: Thirteen patients received 45 cycles of treatment (median, 2; range, 1-8). No dose-limiting toxicities were noted at all bortezomib dose levels when administered with full dose capecitabine and oxaliplatin. The most common grade 3 nonhematologic toxicities during any cycle of therapy included elevated transaminases (3), vomiting, diarrhea, and dehydration (2 each). Only one patient experienced grade 3 peripheral neuropathy in cycle 8. Three objective tumor responses were noted (squamous cell of anus, adenocarcinoma of unknown primary, adenocarcinoma of rectum). Conclusions: Weekly bortezomib can be safely combined with full doses of capecitabine and oxaliplatin. As 1.6 mg/m(2) weekly of bortezomib is the maximum tolerated dose in single-agent studies, no further dose escalation was performed in this study. Preliminary evidence of antitumor activity is demonstrated. The further evaluation of this combination in diseases for which capecitabine and oxaliplatin have efficacy should be considered.
Notes
ISI Document Delivery No.: 261TK Times Cited: 0 Cited Reference Count: 27 Cited References: ADAMS J, 1999, CANCER RES, V59, P2615 ADAMS J, 2002, ONCOLOGIST, V7, P9 AGHAJANIAN C, 2002, CLIN CANCER RES, V8, P2505 ARKENAU H, 2005, J CLIN ONCOL, V23, P3507 CHEN RF, 2005, WORLD J GASTROENTERO, V11, P726 CHUANG SE, 2002, BIOCHEM PHARMACOL, V63, P1709 CUSACK JC, 2001, CANCER RES, V61, P3535 DRAGOVICH T, 2004, J CLIN ONCOL S, V22, P3591 GLOVER KY, 2005, P AN M AM SOC CLIN, P4123 GROTHEY A, 2005, CLIN COLORECTAL C S1, V5, P38 HAMILTON AL, 2005, J CLIN ONCOL, V23, P6107 HOCHSTER HS, 2006, J CLIN ONCOL S, V24, P3510 JATOI A, 2006, ANN ONCOL, V17, P29 KUBICKA S, 2006, GASTROINTEST CANC S, P277 LIND DS, 2001, SURGERY, V130, P363 LIU XF, 2002, CHINESE MED J-PEKING, V115, P998 MACKAY H, 2005, CLIN CANCER RES, V11, P5526 OCEAN AJ, 2005, P GASTR CANC S, P31 OCEAN AJ, 2006, J CLIN ONCOL S, V24, P14040 RAJKUMAR SV, 2005, J CLIN ONCOL, V23, P630 RICHARDSON PG, 2006, J CLIN ONCOL, V24, P3113 RODEL C, 2003, J CLIN ONCOL, V21, P3098 RYAN DR, 2006, CANCER, V107, P2688 SCAIFE CL, 2002, CANCER RES, V62, P6870 SHIELDS AF, 2004, CANCER, V100, P531 SUMPTER K, 2005, BRIT J CANCER, V92, P1976 THERASSE P, 2000, J NATL CANCER I, V92, P205 Cohen, Steven J. Engstrom, Paul F. Lewis, Nancy L. Langer, Corey J. McLaughlin, Susan Beard, Mary Weiner, Louis M. Meropol, Neal J. LIPPINCOTT WILLIAMS & WILKINS; 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA